Skip to content
Assyro AI
Orange Book drug · Brand (NDA)

Ryaltris

Mometasone Furoate; Olopatadine Hydrochloride

RLDNDA 211746 Glenmark Speclt
Approved
Jan 13, 2022
Strengths
1
Listed patents
16

What does the FDA Orange Book show for Ryaltris?

Ryaltris contains Mometasone Furoate; Olopatadine Hydrochloride and is the new drug FDA Orange Book record for NDA 211746. The application has 1 presentation with strength, dosage-form, route, status, RLD/RS, TE, patent, and exclusivity context. Current inventory and clinical labeling are not established without an application-matched source.

FDA application
NDA 211746

New drug application identity from the Orange Book snapshot.

Application holder
Glenmark Specialty Sa

The listed applicant holds the FDA application; this field does not establish the product manufacturer.

Product presentations
1

Each FDA product number remains tied to its own strength, dosage form, route, and status.

Marketing categories
Prescription

Orange Book marketing categories do not establish real-time inventory or commercial availability.

Reference roles
RLD / RS

RLD and RS designations are presentation-specific, not inferred from the trade name.

TE codes
None posted

Therapeutic-equivalence codes apply only within the matching Orange Book product heading.

Listed patents
16

A zero means none appear in this snapshot, not that no patent rights exist.

Exclusivity records
0

FDA exclusivity and listed patent protection are distinct regulatory concepts.

Sourced from the official FDA Orange Book data file · snapshot refreshed

FDA product-presentation matrix

Every product number in this exact application
Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
ProductStrengthDosage form / routeMarketing statusTE codeReference role
0010.025MG/SPRAY;0.665MG/SPRAYSPRAY, METEREDNASALPrescriptionNone posted
RLDRS

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Glenmark Specialty Sa

The Orange Book identifies this organization as the applicant responsible for NDA 211746.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not
FDA marketing status

1 presentation listed as prescription

RX and OTC are Orange Book marketing categories, not real-time inventory signals. Confirm current commercial availability with labeling, the application holder, or an authoritative drug listing.

Therapeutic equivalence

No TE code is posted for this application

No TE code does not mean FDA found the product ineffective or non-equivalent. FDA generally publishes TE evaluations for multisource prescription products; single-source and some other products may have no code.

Patent & exclusivity record

16 listed patent expirations and 0 exclusivity dates remain on or after Jul 26, 2026

The latest future date recorded across those files is Apr 08, 2039. Patent and FDA exclusivity operate independently, can overlap, and do not by themselves predict a generic launch date.

Same-ingredient landscape

0 other ANDAs and 0 other NDAs found

0 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

NDA 211746 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Spray, Metered · Nasal

Mometasone Furoate; Olopatadine Hydrochloride

1 application
Product rows
1
Active applications
1
Active with AB row
0

Why are clinical sections unavailable?

Exact application-label matching status
Exact source match queuedQueue NDA-211746

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Product detail

NDA 211746
RLDRS
Strength
0.025MG/SPRAY;0.665MG/SPRAY
Dosage form
SPRAY, METERED
Route
NASAL
Marketing status
Prescription

Key dates

Approval, patents, exclusivity

  1. Approval

    FDA approval date of this drug product.

    4 yr 7 mo ago

  2. Today

  3. Patent 10016443 expires

    Listed method-of-use patent (U-3297) expiration.

    in 8 yr 3 mo

  4. Patent 10376526 expires

    Listed drug product patent expiration.

    in 8 yr 3 mo

  5. Patent 10517880 expires

    Listed drug product patent expiration.

    in 8 yr 3 mo

  6. Patent 10548907 expires

    Listed method-of-use patent (U-3297) expiration.

    in 8 yr 3 mo

  7. Patent 10561672 expires

    Listed drug product patent expiration.

    in 8 yr 3 mo

  8. Patent 10646500 expires

    Listed method-of-use patent (U-3297) expiration.

    in 8 yr 3 mo

  9. Patent 10758550 expires

    Listed method-of-use patent (U-3296) expiration.

    in 8 yr 3 mo

  10. Patent 10765686 expires

    Listed method-of-use patent (U-3295) expiration.

    in 8 yr 3 mo

  11. Patent 11400101 expires

    Listed method-of-use patent (U-3297) expiration.

    in 8 yr 3 mo

  12. Patent 12064442 expires

    Listed method-of-use patent (U-3297) expiration.

    in 8 yr 3 mo

  13. Patent 9078923 expires

    Listed drug product patent expiration.

    in 8 yr 3 mo

  14. Patent 9370483 expires

    Listed drug product patent expiration.

    in 8 yr 3 mo

  15. Patent 9750754 expires

    Listed drug product patent expiration.

    in 8 yr 3 mo

  16. Patent 9937189 expires

    Listed drug product patent expiration.

    in 8 yr 3 mo

  17. Patent 11679210 expires

    Listed drug product patent expiration.

    in 12 yr 3 mo

  18. Patent 12303635 expires

    Listed drug substance patent expiration.

    in 12 yr 11 mo

Patent & exclusivity timeline

Protection horizon
20262028203020322034203620382040TodayPatent 10016443: 2034-09-04Patent 10016443Patent 10376526: 2034-09-04Patent 10376526Patent 10517880: 2034-09-04Patent 10517880Patent 10548907: 2034-09-04Patent 10548907Patent 10561672: 2034-09-04Patent 10561672Patent 10646500: 2034-09-04Patent 10646500Patent 10758550: 2034-09-04Patent 10758550Patent 10765686: 2034-09-04Patent 10765686Patent 11400101: 2034-09-04Patent 11400101Patent 12064442: 2034-09-04Patent 12064442Patent 9078923: 2034-09-04Patent 9078923Patent 9370483: 2034-09-04Patent 9370483Patent 9750754: 2034-09-04Patent 9750754Patent 9937189: 2034-09-04Patent 9937189Patent 11679210: 2038-09-03Patent 11679210Patent 12303635: 2039-04-08Patent 12303635
Patent expiryExclusivity endToday

Pharmaceutical detail

FDA product record

Active ingredient

MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE

Strength

0.025MG/SPRAY;0.665MG/SPRAY

Dosage form

SPRAY, METERED

Route

NASAL

TE code

Not listed

Application

NDA 211746

Product number

001

Marketing status

Prescription

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10016443in 8 yr 3 mo
U-3297
10376526in 8 yr 3 mo
Product
10517880in 8 yr 3 mo
ProductU-3297
10548907in 8 yr 3 mo
U-3297
10561672in 8 yr 3 mo
Product
10646500in 8 yr 3 mo
U-3297
10758550in 8 yr 3 mo
U-3296
10765686in 8 yr 3 mo
U-3295
11400101in 8 yr 3 mo
U-3297
12064442in 8 yr 3 mo
U-3297
9078923in 8 yr 3 mo
ProductU-3297
9370483in 8 yr 3 mo
Product
9750754in 8 yr 3 mo
ProductU-3297
9937189in 8 yr 3 mo
Product
11679210in 12 yr 3 mo
Product
12303635in 12 yr 11 mo
SubstanceProduct

Active-ingredient family

Brand + generics

This is a reference-listed drug (RLD), the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

No other applications share this active ingredient.

View full Mometasone Furoate; Olopatadine Hydrochloride family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

  • The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
  • RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
  • Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
  • Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
  • The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.

Ryaltris: frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.

Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of NDA 211746 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo